Table 2.
Lipid profile at baseline and at three months after starting anti-TNF therapy in psoriatic arthritis patients.
| Variable | Baseline | Three months | P value |
|---|---|---|---|
| Total cholesterol (mg/dL) | 157.1 ± 32.9 | 163.9 ± 33.8 | 0.30 |
| HDL-c (mg/dL) | 49.7 ± 15.4 | 45.1 ± 11.0 | 0.26 |
| LDL-c (mg/dL) | 91.7 ± 24.4 | 92.7 ± 18.9 | 0.39 |
| VLDL-c (mg/dL) | 25.3 ± 10.6 | 29.7 ± 12.5 | 0.016 |
| Triglycerides (mg/dL) | 126.1 ± 50.1 | 146.5 ± 61.4 | 0.024 |
| Total cholesterol >200 mg/dL | 1 (6) | 0 | 1.0 |
| HDL-c <40 mg/dL(male)/ <50 mg/dL(female) |
5 (37) | 5 (31) | 1.0 |
| LDL-c > 130 mg/dL | 0 | 0 | 1.0 |
| VLDL-c > 40 mg/dL | 1 (6) | 2 (12) | 1.0 |
| Triglycerides > 150 mg/dL | 5 (31) | 8 (50) | 0.47 |
TNF: tumor necrosis factor, HDL-: high-density cholesterol, LDL: low-density cholesterol, and VLDL-c: very-low-density cholesterol.